Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jonathan Green & Allan Lipton. (2010) Anticancer Properties of Zoledronic Acid. Cancer Investigation 28:9, pages 944-957.
Read now
Read now
Articles from other publishers (21)
Jing-Yi Zhang, Li-Jie Zhao & Ya-Tao Wang. (2023) Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer. European Journal of Medicinal Chemistry 262, pages 115925.
Crossref
Crossref
Yashasvi Singh, Sasanka Kumar Barua, Sameer Trivedi, Rajeev TP, Manash Pratim Kashyap, Lalit Kumar Agrawal, Ujjwal Kumar Pathak & Neha Garg. (2023) Skeletal-Related Events in Renal Cell Carcinoma: Prediction With Alkaline Phosphatase (ALP), C-reactive Protein (CRP), Haemoglobin (Hb) and Erythrocyte Sedimentation Rate (ESR) (A.C.H.E.) Score for Risk Stratification. Cureus.
Crossref
Crossref
Mehtap Kara, Tuğçe Boran, Ezgi Öztaş, Ayse Tarbin Jannuzzi, Sibel Özden & Gül Özhan. (2022) Zoledronic acid‐induced oxidative damage and endoplasmic reticulum stress‐mediated apoptosis in human embryonic kidney (HEK‐293) cells. Journal of Biochemical and Molecular Toxicology 36:8.
Crossref
Crossref
Rita Silva Paiva, Inês Gomes, Sandra Casimiro, Isabel Fernandes & Luís Costa. (2020) c-Met expression in renal cell carcinoma with bone metastases. Journal of Bone Oncology 25, pages 100315.
Crossref
Crossref
Chiara Spadazzi, Federica Recine, Laura Mercatali, Giacomo Miserocchi, Chiara Liverani, Alessandro De Vita, Alberto Bongiovanni, Valentina Fausti & Toni Ibrahim. (2019) mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model. Journal of Bone Oncology 16, pages 100227.
Crossref
Crossref
Antonio Maurizi & Nadia Rucci. (2018) The Osteoclast in Bone Metastasis: Player and Target. Cancers 10:7, pages 218.
Crossref
Crossref
Soma Shiva Nageswara Rao Singireesu, Sujan Kumar Mondal, Suresh Yerramsetty & Sunil Misra. (2018) Zoledronic acid induces micronuclei formation, mitochondrial-mediated apoptosis and cytostasis in kidney cells. Life Sciences 203, pages 305-314.
Crossref
Crossref
Masood Umer, Yasir Mohib, Muhammed Atif & Muhammad Nazim. (2018) Skeletal metastasis in renal cell carcinoma: A review. Annals of Medicine and Surgery 27, pages 9-16.
Crossref
Crossref
Diana Lüftner, Daniela Niepel & Guenther G. Steger. (2018) Therapeutic approaches for protecting bone health in patients with breast cancer. The Breast 37, pages 28-35.
Crossref
Crossref
Yusuke Tsuda, Tohru Nakagawa, Yusuke Shinoda, Atsushi Kanatani, Taketo Kawai, Satoru Taguchi, Yukio Yamada, Ryoko Sawada, Haruki Kume, Yukio Homma, Sakae Tanaka & Hirotaka Kawano. (2017) Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis. International Journal of Clinical Oncology 22:3, pages 548-553.
Crossref
Crossref
Xiang Gao, Bo Jiang, Shitao Zou, Ting Zhang, Xiaowei Qi, Linfang Jin, Xiaosong Ge, Shou-Ching Tang, Dong Hua & Weichang Chen. (2015) Zoledronate can promote apoptosis and inhibit the proliferation of colorectal cancer cells. Tumor Biology 36:7, pages 5315-5322.
Crossref
Crossref
Jamal Zekri, Maged Mansour & Syed Mustafa Karim. (2014) The anti-tumour effects of zoledronic acid. Journal of Bone Oncology 3:1, pages 25-35.
Crossref
Crossref
Daniel Keizman, Maya Ish-Shalom, Natalie Maimon & Maya Gottfried. (2013) Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?. World Journal of Urology 32:1, pages 39-45.
Crossref
Crossref
Yosuke Yasuda, Yasuhisa Fujii, Takeshi Yuasa, Shinichi Kitsukawa, Shinji Urakami, Shinya Yamamoto, Junji Yonese, Shunji Takahashi & Iwao Fukui. (2012) Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. International Journal of Clinical Oncology 18:5, pages 877-883.
Crossref
Crossref
Eduard Vrdoljak, Brian Rini, Manuela Schmidinger, Tomislav Omrčen, Laszlo Torday, Cezary Szczylik & Avishay Sella. (2013) Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anti-Cancer Drugs 24:5, pages 431-440.
Crossref
Crossref
Peter F. Mulders. (2012) Current approaches to bone-targeted therapy in genitourinary malignancies. Therapeutic Advances in Urology 4:5, pages 219-232.
Crossref
Crossref
Vincent Lavoué, Florian Cabillic, Olivier Toutirais, Aurélie Thedrez, Benoît Dessarthe, Cécile Thomas de La Pintière, Pascale Daniel, Fabrice Foucher, Estelle Bauville, Sébastien Henno, Florence Burtin, Jean‐Yves Bansard, Jean Levêque, Véronique Catros & Françoise Bouet‐Toussaint. (2011) Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy. International Journal of Cancer 131:4.
Crossref
Crossref
Daniel Keizman, Maya Ish-Shalom, Roberto Pili, Hans Hammers, Mario A. Eisenberger, Victoria Sinibaldi, Ben Boursi, Natalie Maimon, Maya Gottfried, Henry Hayat, Avivit Peer, Svetlana Kovel, Avishay Sella, Raanan Berger & Michael A. Carducci. (2012) Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. European Journal of Cancer 48:7, pages 1031-1037.
Crossref
Crossref
Matti Aapro & Fred Saad. (2012) Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Therapeutic Advances in Urology 4:2, pages 85-101.
Crossref
Crossref
Fred Saad & Jean-Baptiste Lattouf. 2012. Prevention of Bone Metastases. Prevention of Bone Metastases
109
126
.
Fred Saad & James A. Eastham. (2010) Zoledronic Acid Use in Patients With Bone Metastases From Renal Cell Carcinoma or Bladder Cancer. Seminars in Oncology 37, pages S38-S44.
Crossref
Crossref